Literature DB >> 27346340

Ecto-ATPase CD39 Inactivates Isoprenoid-Derived Vγ9Vδ2 T Cell Phosphoantigens.

Georg Gruenbacher1, Hubert Gander1, Andrea Rahm1, Marco Idzko2, Oliver Nussbaumer3, Martin Thurnher4.   

Abstract

In humans, Vγ9Vδ2 T cells respond to self and pathogen-associated, diphosphate-containing isoprenoids, also known as phosphoantigens (pAgs). However, activation and homeostasis of Vγ9Vδ2 T cells remain incompletely understood. Here, we show that pAgs induced expression of the ecto-ATPase CD39, which, however, not only hydrolyzed ATP but also abrogated the γδ T cell receptor (TCR) agonistic activity of self and microbial pAgs (C5 to C15). Only mevalonate-derived geranylgeranyl diphosphate (GGPP, C20) resisted CD39-mediated hydrolysis and acted as a regulator of CD39 expression and activity. GGPP enhanced macrophage differentiation in response to the tissue stress cytokine interleukin-15. In addition, GGPP-imprinted macrophage-like cells displayed increased capacity to produce IL-1β as well as the chemokine CCL2 and preferentially activated CD161-expressing CD4(+) T cells in an innate-like manner. Our studies reveal a previously unrecognized immunoregulatory function of CD39 and highlight a particular role of GGPP among pAgs.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27346340     DOI: 10.1016/j.celrep.2016.06.009

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  21 in total

1.  Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.

Authors:  Morgane Moulin; Javier Alguacil; Siyi Gu; Asmaa Mehtougui; Erin J Adams; Suzanne Peyrottes; Eric Champagne
Journal:  Cell Mol Life Sci       Date:  2017-07-01       Impact factor: 9.261

Review 2.  Regulatory functions of γδ T cells.

Authors:  Christian Peters; Dieter Kabelitz; Daniela Wesch
Journal:  Cell Mol Life Sci       Date:  2018-03-08       Impact factor: 9.261

3.  IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population.

Authors:  Clément Barjon; Henri-Alexandre Michaud; Angeline Fages; Cécile Dejou; Alexandre Zampieri; Laetitia They; Aurélie Gennetier; Françoise Sanchez; Laurent Gros; Jean-François Eliaou; Nathalie Bonnefoy; Virginie Lafont
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 4.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 5.  Targeting immunosuppressive adenosine in cancer.

Authors:  Dipti Vijayan; Arabella Young; Michele W L Teng; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2017-10-23       Impact factor: 60.716

Review 6.  Mevalonate Metabolism in Immuno-Oncology.

Authors:  Georg Gruenbacher; Martin Thurnher
Journal:  Front Immunol       Date:  2017-12-01       Impact factor: 7.561

Review 7.  Tregs: Where We Are and What Comes Next?

Authors:  Hai Zhao; Xuelian Liao; Yan Kang
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

Review 8.  What Else Can CD39 Tell Us?

Authors:  Hai Zhao; Cong Bo; Yan Kang; Hong Li
Journal:  Front Immunol       Date:  2017-06-22       Impact factor: 7.561

9.  Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.

Authors:  Renate Pichler; Georg Gruenbacher; Zoran Culig; Andrea Brunner; Dietmar Fuchs; Josef Fritz; Hubert Gander; Andrea Rahm; Martin Thurnher
Journal:  Cancer Immunol Immunother       Date:  2016-12-22       Impact factor: 6.968

Review 10.  Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.

Authors:  Timm Hoeres; Manfred Smetak; Dominik Pretscher; Martin Wilhelm
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.